Table 5.
Association between presence of FP and the use of antidiabetic agents, statins and antihypertensive agents.
| NAFLD Patients | Grade I FP | Grade II FP | p Value |
|---|---|---|---|
| N = 143 (%) | 59 (41.3%) | 84 (58.7%) | - |
|
Oral antidiabetic agents No Metformin Glimepiride |
56 (94.9%) 13 (15.5%) 4 (4.8%) |
67 (79.8%) 2 (3.4%) 1 (1.7%) |
0.035 * |
| Statin use (%) | 4 (6.8%) | 2 (2.4%) | 0.197 |
| Antihypertensives | 30 (50.8%) | 40 (47.6%) | 0.796 |
| No | 6 (10.2%) | 13 (15.5%) | |
| β-blockers ACE inhibitors | 19 (32.2%) | 23 (27.4%) | |
| Calcium channel blocker | 3 (5.1%) | 7 (8.3%) | |
| Polytherapy | 1 (1.7%) | 1 (1.2%) |
* p values highlighted with* indicate statistical significance—p value < 0.05.